Evidence map›Paper›PMID 34946923›Full record

ReviewGenes2021

The Terpene Mini-Path, a New Promising Alternative for Terpenoids Bio-Production.

Julie Couillaud, Létitia Leydet, Katia Duquesne, Gilles Iacazio

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Enzymatic Glycosylation ofBiomolecules · 2025
    Review
  6. Identification of Black Cumin (Plants (Basel, Switzerland) · 2024
    Article
  7. Review
  8. Confirmation of the stereochemistry of spiroviolene.Beilstein journal of organic chemistry · 2024
    Article
  9. Antileishmanial Activity and In Silico Molecular Docking Studies ofTropical medicine and infectious disease · 2023
    Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Julie CouillaudCentrale Marseille, CNRS, iSm2 Marseille, ISM2 UMR 7313, Aix-Marseille Université, Av. Escadrille Normandie-Niemen, 13013 Marseille, France.ORCID 0000-0001-9861-0242
Létitia LeydetCentrale Marseille, CNRS, iSm2 Marseille, ISM2 UMR 7313, Aix-Marseille Université, Av. Escadrille Normandie-Niemen, 13013 Marseille, France.
Katia DuquesneCentrale Marseille, CNRS, iSm2 Marseille, ISM2 UMR 7313, Aix-Marseille Université, Av. Escadrille Normandie-Niemen, 13013 Marseille, France.ORCID 0000-0001-7668-9180
Gilles IacazioCentrale Marseille, CNRS, iSm2 Marseille, ISM2 UMR 7313, Aix-Marseille Université, Av. Escadrille Normandie-Niemen, 13013 Marseille, France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Terpenoids constitute the largest class of natural compounds and are extremely valuable from an economic point of view due to their extended physicochemical properties and biological activities. Due to recent environmental concerns, terpene extraction from natural sources is no longer considered as a viable option, and neither is the chemical synthesis to access such chemicals due to their sophisticated structural characteristics. An alternative to produce terpenoids is the use of biotechnological tools involving, for example, the construction of enzymatic cascades (cell-free synthesis) or a microbial bio-production thanks to metabolic engineering techniques. Despite outstanding successes, these approaches have been hampered by the length of the two natural biosynthetic routes (the mevalonate and the methyl erythritol phosphate pathways), leading to dimethylallyl diphosphate (DMAPP) and isopentenyl diphosphate (IPP), the two common universal precursors of all terpenoids. Recently, we, and others, developed what we called the terpene mini-path, a robust two enzyme access to DMAPP and IPP starting from their corresponding two alcohols, dimethylallyl alcohol and isopentenol. The aim here is to present the potential of this artificial bio-access to terpenoids, either in vitro or in vivo, through a review of the publications appearing since 2016 on this very new and fascinating field of investigation.

Indexed as

ErythritolHemiterpenesMevalonic AcidOrganophosphorus CompoundsTerpenes3,3-dimethylallyl pyrophosphateErythritolHemiterpenesisopentenyl pyrophosphateMevalonic AcidOrganophosphorus CompoundsTerpenessynthetic biologyterpene mini-pathterpenoids bio-access

Identifiers

PMID34946923
PMCPMC8701039
OpenAlexW4200037924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.